Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM ®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies
Risperidone ISM ® is a newly developed long-acting injectable (LAI) treatment for schizophrenia in adults. In the absence of head-to-head comparisons with other similar antipsychotics, the objective of this study ...
Source: Annals of General Psychiatry - Category: Psychiatry Authors: Pedro S ánchez, Cecilio Álamo, Marcos Almendros, Max Schlueter, Anastasios Tasoulas and Javier Martínez Tags: Research Source Type: research
More News: Abilify | Invega | Invega Sustenna | Psychiatry | Risperdal Consta | Schizophrenia | Study